AstraZeneca and Amgen's Tezspire win in EoE tests whether the ‘late-stage discount’ finally flips on a GI bellwether

AstraZeneca and Amgen reported positive Phase 3 results for Tezspire (tezepelumab) in eosinophilic oesophagitis (EoE), positioning the program as a direct competitive shot on Dupixent’s strongest “structural + symptom” narrative in the GI space. In CROSSING, Tezspire was tested subcutaneously every four weeks against placebo, and the companies said it met the trial’s two co-primary endpoints at Week 24—then sustained improvements through Week 52.

For investors, the most decision-relevant detail is not “worked” versus “didn’t work,” but the shape of the wins: EoE regulators and clinicians care about both histology (inflammation burden) and dysphagia (swallowing outcomes). Tezspire’s mechanism targets TSLP upstream of downstream eosinophilic inflammation, so success here would support the idea that earlier pathway blockade can translate into both measurable esophageal inflammation reduction and meaningful symptom relief.

Late-stage misses tend to reprice a whole company’s risk profile—not because any single pipeline asset matters mechanically, but because the market treats them as evidence about execution repeatability (trial design discipline, patient selection, statistical calibration, and—crucially—learn-and-retry capacity). AstraZeneca has already faced credibility pressure from recent late-stage disappointments, and this Tezspire win is the first late-stage EoE inflection that directly challenges that discounted expectations framework.

However, the reversal only becomes durable if the result “sticks” after the initial headline. That means sustained efficacy (already stated through Week 52), consistent safety/tolerability (especially for chronic GI therapy), and a credible path to commercialization in a market where Dupixent has already earned both physician and patient attention.

This is why the Week 24 co-primary design matters. CROSSING deliberately pairs inflammation control (histology) with the symptom that determines day-to-day quality of life (dysphagia). When both move together, the product can credibly claim comprehensive disease control—something investors should view as a prerequisite for displacing an incumbent rather than merely coexisting as a second-line option.

Dupixent (dupilumab) is the benchmark biologic for EoE, and the practical reason is that EoE is not a transient flare-up. Clinicians manage a chronic disorder with ongoing swallowing impairment risk, and they need endpoints that map to both disease biology and patient experience.

Tezspire’s CROSSING design is aligned to that: histologic remission and DSQ changes are the co-primary endpoints. If those hold across doses (low and high) and persist through Week 52, the program can plausibly offer either (1) first-line biologic adoption in certain phenotypes or (2) an “alternative biologic” pathway where patients or payers prefer a different mechanism of action but still require comparable disease control.

AstraZeneca continues to show a large-scale revenue base and substantial operating profit capacity in recent financial periods, giving it flexibility to continue running and funding late-stage programs even after setbacks.

Using AstraZeneca’s reported financials, revenue in FY2025 was about $58.7B, and revenue over the TTM period through Jun 30, 2026 was about $61.4B, with FY2025 net income of about $10.3B. Those figures don’t prove Tezspire commercial potential, but they do reduce the risk that an execution setback forces aggressive retrenchment that could slow development elsewhere.